Cardamyst FDA approval and launch for PSVT, solid cash, and big expansion upside. Click for more on MIST stock.

North Shore University Hospital’s cardiology team became the first to complete a procedure using the novel OmniaSecure ...

After eight years of Labor, 2025 helped cement the ideological and policy shifts of the new government – headlined in 2025 by ...

Preliminary results from the FULCRUM-VT trial point to a safer, more effective way to treat ventricular tachycardia—a dangerous heart rhythm disorder that can lead to sudden cardiac arrest.

Medtronic this week launched its OmniaSecure defibrillation lead in the U.S., describing it as the world's smallest.

The FDA-approved OmniaSecure defibrillation lead from Medtronic is a thin wire that connects an implantable cardioverter defibrillator to the heart.

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

Interventional cardiologists say some cases that coders flag and submit to the NCDR aren’t in fact problematic.

Objectives: Traditionally, the arterial blood perfusion tube for an extracorporeal left ventricular assist device (LVAD) is placed in the femoral artery, which limits patients' mobility and increases ...

Left ventricular assist device (LVAD) support is an effective therapy for patients suffering from end-stage heart failure.1 The concept was first introduced into mainstream health care in 1994 with ...

For some patients, a percutaneous left ventricular assist device (LVAD) may increase the risk of subsequent aortic regurgitation (AR), especially when there’s a need for longer support, new data ...

Ventricular assist devices are mechanical pumps that take over the function of the damaged ventricle in order to re-establish normal hemodynamics and end-organ blood flow. In addition, VADs unload the ...